As pioneers in digital healthcare, we responded to the world’s need for a solution during the pandemic by introducing the first at-home, digital point-of-care COVID 19 test in 2020. Our Test-to-TreatTM technology provided millions of customers with verified COVID-19 test results and access to treatment within minutes from anywhere.
eMed expanded on this technology by creating eMed Empathetic AITM, a platform that combines advanced technologies with our secure network of certified live proctors and clinicians, to create a human-centric tech approach that delivers convenience, quality, and cost savings to meet the needs of both participants and organizations.
eMed Empathetic AITM supports our convenient at-home kits covering various use cases related to women’s health, COVID / Flu, and drug screening. We have also evolved to offer complete chronic health management programs including our Population Health GLP-1 Program. Through acquisitions we have increased our capabilities to be a multi-national comprehensive service platform that offers multi-diagnostic capabilities with rapid scalability, and have entered the clinical trials space.
Our team is over 100 strong. We combine experience from a multitude of domain areas across leading healthcare services. This combination gives us a special edge to drive clinical excellence. It is also why our technology will continue to expand to various use cases that address a broader range of conditions, making healthcare accessible and affordable for both consumers and enterprises.
